Acibadem Internationals multidisciplinary specialists in JCI-accredited hospitals diagnose and treat related respiratory, liver, and internal medicine conditions for international patients when further evaluation is needed
These shifts in prescribing, regarding choice of substance and brand, could partially be explained by the recommendations issued by the Drug and Therapeutics Committee in Region Stockholm (Kloka listan) [62] and the year of market introductions of Ozempic and Rybelsus
The timing of these symptoms is important: nausea and digestive issues are most pronounced during the initial weeks of treatment and following dose escalations
However, individual responses vary widely, and some patients report increased bowel urgency or loose stools when starting these medications
In a trial involving tirzepatide and semaglutide, GIT adverse events such as nausea, vomiting, and diarrhea were the most commonly reported